Susan Moran
Director/Board Member at BIOATLA, INC.
Net worth: - $ as of 30/04/2024
Susan Moran active positions
Companies | Position | Start | End |
---|---|---|---|
BIOATLA, INC. | Director/Board Member | 01/12/2020 | - |
Independent Dir/Board Member | 01/12/2020 | - | |
TYRA BIOSCIENCES, INC. | Director/Board Member | 07/05/2024 | - |
Independent Dir/Board Member | 07/05/2024 | - |
Career history of Susan Moran
Former positions of Susan Moran
Companies | Position | Start | End |
---|---|---|---|
RAYZEBIO, INC. | Chief Tech/Sci/R&D Officer | 01/07/2021 | 01/05/2024 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Chief Tech/Sci/R&D Officer | 01/03/2018 | 01/06/2021 |
PUMA BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/01/2014 | 01/02/2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2011 | 01/01/2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01/01/2007 | 01/01/2011 |
Training of Susan Moran
University of Virginia | Undergraduate Degree |
Duke University | Undergraduate Degree |
University of Pennsylvania Medical Center | Graduate Degree |
Statistics
International
United States | 10 |
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sectoral
Health Technology | 8 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
BIOATLA, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
TYRA BIOSCIENCES, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Private companies | 3 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
- Stock Market
- Insiders
- Susan Moran
- Experience